Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals' stock price has experienced notable movements in the past six months. The stock was up 33.8% over the past three months and 35.6% year-to-date as of late October 2025, with a robust total return of 68.7% over the past year, influenced by strong new clinical data and pipeline momentum. In July 2025, the company reported strong Q2 2025 earnings, with total revenue reaching $70.0 million and net product sales of LUPKYNIS at $66.6 million, exceeding analyst expectations, and raised its full-year 2025 guidance. The company has been actively returning capital to shareholders through share repurchases, having repurchased 11.2 million shares for $90.8 million in the first six months of 2025, and the board approved an additional $150 million increase to the buyback plan. Earlier in 2025, the company faced minor social media-related noise, but management quickly reaffirmed the integrity of LUPKYNIS's safety profile. In late 2024, the stock saw a significant run-up, nearly 60% since July 2024, driven by solid Q3 results and announced cost reduction measures. Buyout speculation has also been a consistent rumor impacting the stock in recent years.

Information explicitly detailing demand seasonality for Aurinia Pharmaceuticals' products and services was not found. However, the company has reported consistent revenue growth and increasing net product sales for LUPKYNIS across quarters, suggesting a relatively stable demand rather than significant seasonality.

Aurinia Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with unmet medical needs. The company operates in the Healthcare sector, specifically in Biotechnology & Life Sciences and Immunology Biopharmaceuticals industries. Its primary product is LUPKYNIS (voclosporin), an FDA-approved oral therapy for active lupus nephritis (LN) in adults. Aurinia is also developing AUR200 (aritinercept) for potential treatment of various autoimmune diseases.

Aurinia Pharmaceuticals has a global geographic footprint, with LUPKYNIS adoption expanding internationally. The company partners with Otsuka Pharmaceutical for international distribution, and Otsuka has filed a new drug application for voclosporin in Japan, indicating planned expansion into the Japanese market.

Aurinia Pharmaceuticals' reputation has been generally stable in the past year, though it experienced some minor events. Earlier in 2025, the company addressed "minor social media-related noise" and management promptly reaffirmed the safety profile and regulatory standing of LUPKYNIS. Additionally, there was a news report in September 2025 about Aurinia responding to a now-retracted LinkedIn post.

Aurinia Pharmaceuticals is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 44.23% of the company, Aurinia Pharmaceuticals insiders own 12.63%, and retail investors hold 43.13%. As of September 2025, institutional investors collectively own over 50% of the company. Major institutional owners include Tang Capital Management LLC, BlackRock, Inc., NEA Management Company, LLC, State Street Corp, Morgan Stanley, Vanguard Group Inc, Armistice Capital, LLC, Geode Capital Management, LLC, and Qube Research & Technologies Ltd. The largest individual shareholder is Kevin Tang, who owns 11.33 million shares, representing 8.61% of the company. Insiders have also been acquiring shares, with Kevin Tang acquiring 200,000 shares in August 2025.